We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lateral Flow Immunoassay Evaluated for Respiratory Samples

By LabMedica International staff writers
Posted on 08 Jan 2013
Rapid point-of-care pathogen detection remains a challenge, especially for Staphylococcus aureus detection in respiratory samples. More...


A rapid S. aureus–specific lateral flow immunochromatography (LFI) test has been developed using a specific monoclonal antibody to the S. aureus cell-wall peptidoglycan.

Scientists at King's College London (UK) used a LFI strip and modified the antigen target and capture/detection antibody to achieve greater sensitivity and specificity. They used an affinity-purified mouse monoclonal anti-S. aureus antibody that was raised specifically against S. aureus cell-wall peptidoglycan and conjugated with gold colloid. They used samples from six volunteers with severe asthma as well as spiked sputum and bronchial lavage specimens.

The LFI test was shown to be specific for S. aureus with no signal development for other Staphylococcal species or common respiratory pathogens. Evaluation of S. aureus isolates spiked into induced sputum and bronchoalveolar lavage samples derived from severe asthmatic patients showed a detection limit of 106 colony forming units (CFU)/mL for the LFI. The LFI test strips positively detected methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA). The test was also shown to successfully detect S. aureus in one sample independently determined to be S. aureus positive by quantitative polymerase chain reaction.

The authors concluded that that an LFI detection limit of equal to or greater than 106 CFU/mL may be sufficiently sensitive to screen for preliminary information in a number of applications, but LFI tests with lower detection limits of less than 104 CFU/mL would be more clinically relevant. Further studies are currently ongoing to lower the detection limits of the LFI test and evaluate the robustness of the assay for a number of different applications. The ability of the LFI test to rapidly detect S. aureus in clinical respiratory samples suggests that it might be a useful platform for further development of point-of-care diagnostic applications. The study was published in the January 2013 edition of the journal Diagnostic Microbiology & Infectious Diseases.

Related Links:
King's College London



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.